Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update

Posted by Teresa Graham on Jul 30th, 2024

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) was the target of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 1,900,000 shares, a decrease of 15.2% from the June 30th total of 2,240,000 shares. Based on an average daily volume of 950,400 shares, the short-interest ratio is currently 2.0 days.

Matinas BioPharma Stock Performance

Matinas BioPharma stock opened at $0.17 on Tuesday. The stock has a market cap of $41.39 million, a P/E ratio of -1.38 and a beta of 1.70. Matinas BioPharma has a 52 week low of $0.11 and a 52 week high of $0.89.

Matinas BioPharma (NYSEAMERICAN:MTNB – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.03) EPS for the quarter.

Institutional Investors Weigh In On Matinas BioPharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Private Advisor Group LLC increased its stake in Matinas BioPharma by 31.1% during the fourth quarter. Private Advisor Group LLC now owns 337,330 shares of the company’s stock worth $73,000 after acquiring an additional 80,000 shares during the last quarter. Alliance Wealth Management Group acquired a new stake in shares of Matinas BioPharma in the second quarter valued at $299,000. Finally, Arkadios Wealth Advisors grew its stake in shares of Matinas BioPharma by 16.1% in the fourth quarter. Arkadios Wealth Advisors now owns 1,624,000 shares of the company’s stock valued at $351,000 after buying an additional 225,000 shares in the last quarter. Institutional investors and hedge funds own 11.77% of the company’s stock.

Matinas BioPharma Company Profile

(Get Free Report)

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.